Loading...
XNAS
MEDP
Market cap15bUSD
Jul 10, Last price  
538.23USD
1D
0.51%
1Q
9.06%
Jan 2017
1,392.18%
IPO
1,819.51%
Name

Medpace Holdings Inc

Chart & Performance

D1W1MN
XNAS:MEDP chart
P/E
34.07
P/S
6.08
EPS
15.80
Div Yield, %
Shrs. gr., 5y
-4.77%
Rev. gr., 5y
22.27%
Revenues
2.53b
+19.97%
272,890,000290,041,000359,059,000421,582,000436,152,000704,589,000860,969,000925,925,0001,142,377,0001,459,996,0001,885,842,0002,109,054,0002,530,234,000
Net income
451m
+11.56%
24,844,000-15,572,000-8,673,00013,425,00039,122,00073,185,000100,443,000145,384,000181,848,000245,368,000282,810,000404,386,000451,123,000
CFO
713m
+17.15%
98,142,00075,202,00085,870,00091,732,00097,385,000156,584,000201,867,000258,676,000263,327,000388,050,000433,374,000608,815,000713,223,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
IPO date
Aug 11, 2016
Employees
5,600
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT